PTGS2 and gastric ulcer: The ability to selectively inhibit COX-2 with no impact on COX-1 is a pharmacologically preferred feature of anti-inflammatory drugs, essential for preventing undesirable adverse treatment effects, such as gastric ulceration and decreased platelet aggregation, often observed for nonselective COX inhibitors [39].